Relating to required reports of certain vaccine-related or drug-related adverse events.
Summary
SB 269 creates new reporting duties for physicians concerning serious adverse events tied to certain vaccines and drugs. The bill applies only to products that are experimental or investigational, or that have been authorized or approved for emergency use by the U.S. Food and Drug Administration, and it excludes products used as part of a clinical trial. A “serious adverse event” is defined broadly to include death, life-threatening events, hospitalization, persistent incapacity, congenital anomalies, or other medically important conditions that may require intervention to prevent those outcomes.
Under the bill, a physician who diagnoses a condition related to such an event and knows the patient received the covered vaccine or drug must report the event within the federal reporting systems: the Vaccine Adverse Event Reporting System (VAERS) for vaccines and MedWatch for drugs. The reporting obligation applies if the event occurs within one year of vaccination or use. The Texas Medical Board is authorized to take corrective or disciplinary action against physicians who fail to comply, with repeat violations treated as professional discipline and violations retained in the physician’s permanent record. The Health and Human Services Commission’s executive commissioner must adopt rules to implement the law, and the act takes effect September 1, 2025.
Impact
The bill amends the Texas Health and Safety Code by adding Sections 161.0103 and 431.1145, creating state-law reporting requirements for physicians regarding serious adverse events associated with certain vaccines and drugs. It also ties compliance to Texas Medical Board enforcement, giving the board authority to impose non-disciplinary corrective action for a first violation and disciplinary action for subsequent violations. The measure affects physicians, the Texas Medical Board, and reporting obligations connected to federal adverse-event surveillance systems, while excluding clinical-trial use from its scope.
Sentiment
The bill appears to have been generally supported in the Legislature, especially in the Senate where it passed unanimously, 31-0, and later the Senate concurred in the House amendment unanimously as well. In the House, however, the bill drew more opposition, passing 104-37 with three present not voting, indicating meaningful but not majority resistance. The voting pattern suggests broad agreement on the need for adverse-event reporting, but more division in the House over the bill’s scope and enforcement approach.
Contention
The main points of contention are likely the breadth of the reporting mandate and the enforcement mechanism. Critics may object to requiring physicians to report serious adverse events for experimental or emergency-use vaccines and drugs, especially because the bill links noncompliance to Texas Medical Board discipline and permanent recordkeeping. Supporters likely view the measure as a transparency and patient-safety requirement that strengthens reporting to federal systems. The House vote margin suggests the strongest disagreement centered on whether the state should impose this level of mandatory reporting and professional discipline, while the Senate showed little to no opposition.